Puma Biotechnology (PBYI) Share Price Surges 23.27% on Outperforming Q3 Earnings Report

The share price rose to its highest level so far this month, with an intraday gain of 23.27%.

Puma Biotechnology’s (PBYI) recent surge follows a Q3 2025 earnings report that significantly outperformed expectations. Adjusted earnings per share (EPS) reached $0.21, surpassing the Zacks Consensus Estimate by 133.33%. Despite a 32.3% year-over-year revenue decline to $54.5 million, the company’s adjusted net income rose to $10.5 million, driven by cost-cutting measures and robust demand for its flagship drug, NERLYNX. Puma also raised full-year 2025 guidance, projecting net product revenue of $198–$200 million and net income of up to $29 million, citing 8% higher U.S. NERLYNX sales and pricing strength.

Analysts remain cautious despite the strong results. Puma holds a Zacks Rank #3 (Hold), with a median 12-month price target of $4.00—22.5% below its November 6 closing price of $4.95. The stock’s P/E ratio has climbed to 14, reflecting skepticism about sustaining growth amid a single-product reliance on NERLYNX. While pipeline advancements for alisertib, a potential treatment for lung and breast cancer, could offer future catalysts, clinical data is not expected until mid-2026. Investors are advised to monitor upcoming trials and earnings revisions, as the company’s long-term success hinges on diversifying its therapeutic portfolio and maintaining cost discipline in a competitive biopharma landscape.